UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2018	Jul. 31, 2017
Operating revenue:
Oncology solutions	$ 6,225	$ 5,033
Total operating revenue	6,225	5,033
Costs and operating expenses:
Cost of oncology solutions	3,083	2,642
Research and development	1,088	1,118
Sales and marketing	518	683
General and administrative	1,055	1,209
Total costs and operating expenses	5,744	5,652
Income (Loss) from operations	481	(619)
Other income (expense):
Other income (expense)	1	(51)
Total other income (expense)	1	(51)
Income (Loss) before provision for income taxes	482	(670)
Provision for income taxes	0	4
Net income (loss)	$ 482	$ (674)
Net income (loss) per common share outstanding
Net income (loss) per common share outstanding, basic (in dollars per share)	$ 0.04	$ (0.06)
Net income (loss) per common share outstanding, diluted (in dollars per share)	$ 0.04	$ (0.06)
Weighted average common shares outstanding
Weighted average common shares outstanding, basic (in shares)	11,012,281	10,982,159
Weighted average common shares outstanding, diluted (in shares)	12,618,021	10,982,159